Regeneron Pharmaceuticals (REGN) said Thursday it won $135.6 million dollars in compensatory damages and $271.2 million in punitive damages in its antitrust case against Amgen (AMGN).

A jury in the U.S. District Court for the District of Delaware found Amgen using cross-therapeutic bundled rebates to block Regeneron's cholesterol drug Praluent from competing in the market, Regeneron said in a statement.

Amgen allegedly leveraged its anti-inflammatory drugs Enbrel and Otezla to convince pharmacy benefit managers to select its Repatha as the exclusive cholesterol treatment over Praluent, the company said.

"Amgen threatened to withhold rebates unless PBMs preferred Repatha and excluded Praluent," the company said in the statement.

Amgen didn't immediately respond to a request for comment from MT Newswires.

Regeneron shares rose 2.4% in regular trading Thursday, and Amgen gained 3.6%.